Tolbutamide

CAT: 0804-HY-B0401-01Size: 500 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0401-01Size:500 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete[1][2][3][4].
CAS Number
[64-77-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Na+/K+ ATPase
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-Kinase/protease
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Tolbutamide.html
Purity
99.96
Solubility
DMSO : ≥ 34 mg/mL
Smiles
O=S(C1=CC=C(C)C=C1)(NC(NCCCC)=O)=O
Molecular Formula
C12H18N2O3S
Molecular Weight
270.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Sánchez‐Alvarez R, et al. Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up‐regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation [J]. Glia, 2006, 54 (2) : 125-134.|[2]Hœy M, et al. Tolbutamide stimulates exocytosis of glucagon by inhibition of a mitochondrial‐like ATP‐sensitive K+ (KATP) conductance in rat pancreatic A‐cells [J]. The Journal of Physiology, 2000, 527 (1) : 109-120.|[3]Williams A J K, et al. Tolbutamide reduces the incidence of diabetes mellitus, but not insulitis, in the non-obese-diabetic mouse [J]. Diabetologia, 1993, 36: 487-492.|[4]Belisle R J, et al. Tolbutamide treatment of pregnant mice: repeated administration reduces fetal lethality [J]. Teratology, 1976, 13 (1) : 65-70.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

Popular Products